OMNI® surgical system versus iStent inject® with concomitant cataract surgery for the treatment of mild-to-moderate primary open-angle glaucoma in the United States: a cost utility analysis

[1]  Tumaini R. Coker,et al.  Screening for Primary Open-Angle Glaucoma: US Preventive Services Task Force Recommendation Statement. , 2022, JAMA.

[2]  S. Glied,et al.  Cost-Effectiveness Analysis of Minimally Invasive Trabecular Meshwork Stents with Phacoemulsification. , 2021, Ophthalmology. Glaucoma.

[3]  Nan Zhang,et al.  Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review , 2021, Scientific Reports.

[4]  C. Schweitzer,et al.  A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France , 2021, PloS one.

[5]  E. Miller-Ellis,et al.  Clinical and Economic Burden of Glaucoma by Disease Severity: A US Claims-Based Analysis. , 2020, Ophthalmology. Glaucoma.

[6]  J. Dickerson,et al.  Canaloplasty and trabeculotomy ab interno with the OMNI system combined with cataract surgery in open-angle glaucoma: 12-month outcomes from the ROMEO study , 2020, Journal of cataract and refractive surgery.

[7]  Philip P. Chen,et al.  Primary Open-Angle Glaucoma Preferred Practice Pattern®. , 2020, Ophthalmology.

[8]  J. Dickerson,et al.  Canaloplasty and Trabeculotomy with the OMNI System in Pseudophakic Patients with Open-Angle Glaucoma: the ROMEO Study. , 2020, Ophthalmology. Glaucoma.

[9]  Paul P. Lee,et al.  Cost-Utility Analysis of Glaucoma Medication Adherence. , 2019, Ophthalmology.

[10]  Jonathan D. Solomon,et al.  Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results. , 2019, Ophthalmology.

[11]  Gary C. Brown,et al.  Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma. , 2019, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[12]  Louis P Garrison,et al.  A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  Maria A. Woodward,et al.  Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs. , 2017, Ophthalmology.

[14]  F. Medeiros,et al.  The pathophysiology and treatment of glaucoma: a review. , 2014, JAMA.

[15]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  Paul P. Lee,et al.  An assessment of the health and economic burdens of glaucoma. , 2011, American journal of ophthalmology.

[17]  J. Severens,et al.  The relationship between visual field loss in glaucoma and health-related quality-of-life , 2010, Eye.

[18]  M. C. Leske,et al.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. , 2002, Archives of ophthalmology.

[19]  W. M. Grant,et al.  Diamox (acetazoleamide) in treatment of glaucoma. , 1954, A M A Archives of Ophthalmology.